Linagliptin Sandoz

Linagliptin, the active ingredient in Linagliptin Sandoz, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of blood glucose in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

GNH USA supplies Linagliptin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export. Customers benefit from reliable logistics and dedicated technical support throughout the procurement process.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting plasma glucose and improves overall glycemic control. - Type 2 diabetes mellitus: reduces HbA1c levels when added to diet and exercise. - Type 2 diabetes mellitus: enhances post‑prandial glucose regulation as part of combination therapy.

Linagliptin may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Nasopharyngitis - Headache - Dizziness - Upper respiratory tract infection - Gastrointestinal discomfort (e.g., nausea, abdominal pain) - Back pain

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions (e.g., angioedema, anaphylaxis) - Hepatic injury - Bullous pemphigoid - Stevens‑Johnson syndrome - Severe hypoglycemia when combined with insulin or sulfonylureas

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure patient safety.

- Renal impairment: assess kidney function; dose adjustment may be required. - Hepatic impairment: monitor liver enzymes regularly. - Elderly patients: observe for signs of hypoglycemia, especially if used with other glucose‑lowering agents. - Concomitant sulfonylureas or insulin: increased risk of hypoglycemia; adjust therapy as needed. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at room temperature: keep in the original container, protect from moisture and heat.

Linagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with insulin: may cause severe hypoglycemia. - Combination with sulfonylureas: heightened risk of hypoglycemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: monitor renal function and electrolytes. - Rifampin: may reduce linagliptin effectiveness. - ACE inhibitors or ARBs: observe blood pressure and renal parameters. - Anticoagulants (e.g., warfarin): monitor INR as glycemic changes may affect anticoagulation. - Antihypertensive agents: watch for additive blood pressure effects.